Clinical characteristics and prognostic model for extensive-stage small cell lung cancer: A retrospective study over an 8-year period.

The first-line treatment of SCLC patients admitted to our hospital in the past 8 years was relatively standardized, and the progression-free survival and OS were slightly longer than those reported in the literature. We developed a prognostic risk score model for extensive-stage SCLC to calculate individual survival in clinical practice.